Introduction
============

Chloroquine (CQ) and hydroxychloroquine (HCQ) are both 4-aminoquinoline agents that have been used for more than 70 and 50 years, respectively, to prevent or to treat malarial infections and later also for treating discoid and systemic lupus erythematosus and rheumatoid arthritis. Although HCQ and CQ differ only by one hydroxyl group, the addition of this hydroxyl group results in an important decrease in toxicity, while the efficacy remains constant, at least for malaria \[[@ref1]\]. Both drugs are available as generic products and mentioned on the WHO list of essential medicines. Frequently used trade names of CQ include Avloclor, Nivaquine or Aralen, and the most frequently used trade name for HCQ is Plaquenil.

The mechanisms of action of CQ and HCQ against the malarial *Plasmodium* parasite and against the auto-immune disorders for which they are approved are well known \[[@ref2]--[@ref6]\].

Dosage
======

The dosage of CQ depends on the indication \[[@ref3], [@ref4]\]. It should be noted that CQ is often marketed as chloroquine phosphate (CQ-phosphate) in tablets of 250 mg, which corresponds to about 150 mg of CQ. All doses mentioned below are doses of CQ-phosphate. High doses (1 g of CQ-phosphate per day) are administered in acute phases of malaria or amoebic hepatitis, but only for one or two days. The usual dose for long-term use (rheumatoid arthritis and lupus) is 250 mg of CQ-phosphate per day. For HCQ, doses for long-term use range between 200 and 400 mg per day. Long-term administration of CQ and HCQ in children is not recommended, but doses for long-term treatment between 2 and 5 mg/kg for HCQ have been reported \[[@ref7]\].

Toxicity
========

Short-term administration of CQ or HCQ rarely causes severe side effects. Longer exposure has been associated with some serious though uncommon adverse events \[[@ref3]\], including cardiomyopathy \[[@ref8]\], irreversible retinal toxicity \[[@ref9], [@ref10]\], bone marrow suppression \[[@ref11]\] and hypoglycaemia \[[@ref12]\]. The risk of retinopathy is increased with large cumulative doses of HCQ (\>1000 g). However, daily doses up to 400 mg of HCQ or 250 mg CQ for several years are considered to carry an acceptable risk for CQ-induced retinopathies, with the exception of individuals of short stature \[[@ref13]\]. It is advised that patients receiving chronic CQ or HCQ therapy be monitored through regular ophthalmic examinations (3--6 month intervals), full blood counts and blood glucose level checks. CQ has been associated with some cases of diffuse parenchymal lung disease and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome \[[@ref3]\]. In case of long-term HCQ exposure, skeletal muscle function and tendon reflexes should be monitored for weakness.

For both CQ and HCQ, specific caution is advised in patients suffering from impaired hepatic function (especially when associated with cirrhosis), porphyria, renal disease, epilepsy, psoriasis, glucose-6-phosphate dehydrogenase deficiency and known hypersensitivity to 4-aminoquinoline compounds \[[@ref3]\].

Bioavailability
===============

CQ and HCQ are amphiphilic weak bases with the ability to cross cell membranes easily, which is important for their mechanism of action in malaria treatment and prophylaxis. CQ and HCQ are partially protonated at the physiologic pH (7.4), but they can be trapped in lysosomes (pH 4--5) because of bi-protonation \[[@ref14]\]. CQ has pKa values of 8.4 and 10.2, while HCQ has pKa values of 8.3 and 9.7 \[[@ref14], [@ref15]\].

Both CQ and HCQ have a high bioavailability, 89% and 74% respectively, and a large distribution volume after oral administration. Roughly, 50%--70% of CQ is protein-bound in the plasma \[[@ref3]\]. The terminal elimination half-life of CQ is 1--2 months and for HCQ approximately 50 days in blood (32 days in plasma). Both drugs are partially metabolised by hepatic dealkylation, but they differ in the number of the metabolites produced. The active metabolites of CQ are monodesethylchloroquine and bisdesethylchloroquine, while HCQ has one extra active metabolite, namely desethylhydroxychloroquine. Moreover, CQ and HCQ are slowly excreted and may still be detected in urine several months after administration \[[@ref3], [@ref4], [@ref9]\].

Pre-clinical evidence in cancer---*in vivo*
===========================================

CQ and HCQ have been extensively studied both *in vitro* and *in vivo* in various cancer types. This paper focuses on the results from *in vivo* research, since this is most relevant to clinical practice. Both drugs can be administered as monotherapy or as adjuvant agents to increase the efficacy and to limit drug resistance of standard anti-cancer therapy.

### Monotherapy

[Table 1](#table1){ref-type="table"} lists the main characteristics \[animal models, tumour types, animal (H)CQ doses and human equivalent doses (HED)\] of the *in vivo* studies performed with CQ or HCQ alone.

Starting with *in vivo* studies that observed beneficial effects of CQ administration in cancer, Jutten *et al* noted a delayed tumour growth in mice bearing epidermal growth factor receptor (EGFR)-overexpressing glioblastoma xenografts in response to CQ administration. In addition, the time to reach four times the initial tumour volume was significantly longer in the CQ-treated group \[[@ref16]\]. Kim *et al* confirmed this observation in another glioblastoma xenograft mouse study, where CQ was injected intracranially. They observed that the number of mitotic cells was significantly reduced and the number of apoptotic cells was increased after CQ administration \[[@ref17]\]. In addition, a significant reduction of tumour volume and tumour incidence was shown by Song *et al* \[[@ref18]\] in mice bearing liver cancer stem cells and Hu *et al* \[[@ref19]\] observed significant tumour growth and weight reduction in an orthotopic xenograft model of liver cancer after CQ administration. Lakhter *et al* \[[@ref20]\] demonstrated that CQ significantly reduced both tumour volume and tumour mass in a human melanoma xenograft model. Zheng *et al* \[[@ref21]\] showed reduced tumour progression and prolonged survival time (not significant) in colon cancer-bearing mice when administering either 25 or 50 mg/kg of CQ.

Doses of 25 and 50 mg/kg of CQ both significantly increased survival time and reduced primary tumour volume in mice implanted with a highly metastasizing breast cancer cell line, as shown by Jiang *et al*. Interestingly, the number and diameter of lung metastases was reduced as well, and CQ enhanced tumour cell apoptosis in the high dose group \[[@ref22]\].

The incidence of mammary tumours and their growth rate was significantly lower and tumour onset was delayed in CQ-pre-treated rats after being subjected to mammary adenocarcinoma induction using N-methyl-N-nitrosourea (NMU), as shown by Loehberg *et al*. In wild-type BALB/c mice transplanted with mammary ducts of BALB/c p53-null mice, CQ pre-treatment did not affect tumour incidence \[[@ref23]\]. Maclean *et al* confirmed that CQ could not prevent spontaneous tumour formation in p53-deficient mice. In contrast, intermittent CQ administration significantly reduced the tumour development and doubled the overall survival (OS) of E*μ*-Myc mice \[[@ref24]\].

Furthermore, Sun *et al* showed that CQ administration is effective in reducing tumour growth in rats with established hepatocarcinoma. In contrast, CQ promoted tumour development in the earlier so-called dysplastic stage, clearly illustrating the dual role of autophagy in tumour formation (see section on mechanisms of action) \[[@ref25]\]*.* Finally, Maes *et al* \[[@ref26]\] reported that either a dose of 50 mg/kg or a dose of 100 mg/kg of CQ can reduce tumour growth and cell proliferation*,* dependent on the cell type*.* Of note, this study showed that CQ not only inhibits autophagy but also affects the tumour microenvironment and tumour vasculature. The exact working mechanisms will be clarified in the section on mechanisms of action.

Some studies noted that the efficacy of CQ application in anti-cancer therapy depends on the tumour type that is being treated and suggested that the autophagy dependency of tumour cells might play a role \[[@ref27], [@ref28]\]. For example, tumour growth was significantly reduced in an MDAMB231 xenograft mouse model, but not in an MCF-7 xenograft mouse model, while both models showed signs of autophagy inhibition after CQ treatment \[[@ref28]\]*.* A similar observation can be made when comparing CQ efficacy in pancreatic cancer mouse models and a lung cancer mouse model: CQ significantly slowed down tumour growth and increased survival in the first, but not in the latter \[[@ref27]\]. Another study by Hiraki *et al* \[[@ref29]\] investigated the effects of CQ in various *in vivo* cancer models and demonstrated that CQ is more effective in connective tissue-rich Bashford and Brown--Pearce tumours than in Ehrlich, Yoshida and MH134 tumours.

A lack of efficacy in certain tumour models could potentially be explained by a study performed by Pellegrini *et al* exploring the effects of CQ under acidic conditions, which mimics the tumour environment. CQ bi-protonation under those conditions could impede cytotoxicity, because the cellular uptake of CQ is reduced. This observation highlights a possible limitation of CQ in anti-cancer therapy. However, the sensitivity of tumour cells might be restored using tumour pH-modulating agents \[[@ref30]\]*.* Ironically, hypoxic cells that can increase acidification of the extracellular space through anaerobe glycolysis are often more autophagy-dependent and, therefore, more sensitive to CQ treatment, as shown by *in vitro* studies \[[@ref31]\]*.*

A limited amount of studies reported potential detrimental effects of CQ and HCQ in *in vivo* cancer models. First, CQ pre-treatment of rats one week before a subcutaneous injection with mammary adenocarcinoma and follow-up treatment for 18 days following this event significantly enhanced tumour weight and volume in these rats \[[@ref32]\]. Second, in a 1966 paper, very low CQ doses (0.2 mg/2 days) led to a more infiltrative morphological pattern of the advancing margin of subcutaneously transplanted mammary carcinoma in mice \[[@ref33]\]. Third, malignant tumour growth and metastasis of Ras(V12) cells is observed in transgenic drosophila models after CQ administration \[[@ref34]\]*.* Importantly, HCQ promoted tumour growth in Ras-driven pancreatic tumours developing without p53(Kras^G12D/+^p53^--/--^) \[[@ref35]\]. Collectively, these results on a possible detrimental effect of (H)CQ emphasise the importance of the specific tumour setting and tumour characteristics when targeting autophagy (see section on mechanisms of action) \[[@ref35], [@ref36]\]*.*

### Combination therapy

[Table 2](#table2){ref-type="table"} summarises the information from articles that studied the effect of CQ (*n* = 46) or HCQ (*n* = 5) *in vivo* in combination with other therapies. A more interesting and still under-explored treatment approach for a complex disease such as cancer is to combine various anti-cancer agents acting at different levels in the tumour cells and microenvironment \[[@ref37]\]. Interestingly, CQ and HCQ have already been tested in combination with over 40 other drugs in preclinical cancer research. Both CQ and HCQ can effectively increase the efficacy of various anti-cancer drugs, which is further explained in the section on mechanisms of action. Therapies used in combination with CQ or HCQ include chemotherapeutic drugs, tyrosine kinase inhibitors, various monoclonal antibodies, hormone therapies and radiotherapy ([Table 2](#table2){ref-type="table"}).

Human data
==========

Numerous clinical trials in which either CQ or HCQ is being used to treat patients with a range of cancer types are registered in clinical trial databases. In clinical trials, these drugs are most often administered in combination with other anti-cancer agents. More information on the registered clinical trials is provided in [Tables 3](#table3){ref-type="table"} and [4](#table4){ref-type="table"}, for CQ and HCQ, respectively. Few trials have been completed. Therefore, limited published data are available on the safety and therapeutic efficacy of these antimalarial drugs in cancer. A schematic overview of the published clinical trial data of CQ and HCQ can be found in [Tables 5](#table5){ref-type="table"} and [6](#table6){ref-type="table"}, respectively.

In the next section, the clinical effects of CQ and HCQ will be discussed separately because important differences can be observed in toxicity and efficacy of both drugs.

CQ
--

### Glioma and brain metastases

In May 1998, one of the first clinical trials on CQ use in cancer was started, which was an open, prospective, randomised controlled study with 18 glioblastoma multiforme (GBM) patients \[[@ref38]\]. The test group consisted of nine patients who received 150 mg CQ daily after resection of the lesion, in addition to radiotherapy (total dose of 6000 Gy) and four cycles of carmustine-chemotherapy every six weeks (200 mg/m^2^), while the nine patients in the control group received placebo instead of CQ. In the abstract of this study, the authors reported that adjuvant CQ administration significantly enhanced patient survival \[33 ± 5 months for CQ-treated patients and 11 ± 2 months for controls (p \< 0.0002)\]. Due to some inconsistencies in the report, the calculation of the mean survival in the CQ-treated group is unclear, but the Kaplan Meier analysis remains significant. A higher seizure frequency was observed in the CQ-treated group and could not be explained. However, standard antiepileptic treatment was reported to easily suppress these seizures. The same group of researchers started a similar randomised, double blind, placebo-controlled study in October 2000 \[[@ref39]\]. In this second study, 15 GBM patients received 150 mg CQ each day for 12 months after surgery in combination with their conventional anti-cancer therapy, four cycles of carmustine-chemotherapy every five weeks (200 mg/m^2^) and a total radiation dose of 60 Gy; the other 15 patients received adjuvant placebo treatment. A median survival time of 24 months was observed in the CQ-treated group, as compared with 11 months in the control group. In addition, the hazard ratio for death was approximately half as large in the patients receiving CQ though this was not statistically significant (hazard ratio: 0.52, \[95% CI 0.21--1.26, *p* = 0.139\]). No important adverse effects were noted in this trial. The small sample size is an important limitation in both studies, and larger clinical trials are needed to confirm the efficacy of CQ in GBM therapy \[[@ref39], [@ref40]\]. In a retrospective study, the same research group looked at data collected over five years from 41 GBM patients in Mexico who received adjuvant CQ therapy and did not participate in the previously mentioned clinical trials \[[@ref41]\]. The mean survival time of these CQ-treated patients was significantly longer compared with a control group of 82 glioblastoma patients \[25 ± 3.4 months and 11.4 ± 1.3 months after surgery respectively (*p* = 0.000)\].

After the observation of promising outcomes in five recurrent GBM patients treated with 250 mg CQ a day and reirradiation for 20 months \[[@ref42]\], a phase-2 clinical trial tested the effects of CQ as a radio-sensitising agent in patients with brain metastases \[[@ref43]\]. In this trial, 39 patients were administered whole-brain irradiation (30 Gy in 10 fractions over two weeks) in combination with a daily dose of 150 mg CQ for four weeks, while 34 patients received placebo instead of CQ in addition to the same radiation treatment. The overall response rate or OS did not improve after CQ administration. However, the progression-free survival of brain metastases rate was increased (CQ-treated group: 83.9% \[95% CI 69.4--98.4\] and control group: 55.1% \[95% CI 33.6--77.6\] (at one year), relative risk: 0.31 \[95% CI 0.1--0.9, *p* = 0.046\]). The absence of adverse effects and the improved local control of brain metastases indicate that CQ might be a useful addition to whole brain irradiation in patients with brain metastases. In a prospective, single-cohort study of 20 patients with brain metastases from solid tumours, 250 mg CQ daily was administered for five weeks in combination with whole-brain irradiation \[[@ref44]\]. The intracranial response rate corresponded to an objective clinical response of 93% after three months of whole-brain irradiation, there was a slight, positive trend in OS (median OS of 5.7 months, compared with 4.2 months for patients in class II estimated by the radiation therapy oncology group recursive partitioning analysis), and no adverse reactions were detected. Finally, two case reports mentioned unusual skin reactions after concomitant use of CQ and radiation, illustrating the radio-sensitising effect of CQ \[[@ref45], [@ref46]\].

In a paediatric patient with a recurrent BRAF V600E mutant brainstem ganglioglioma, tumour growth was blocked and vemurafenib sensitivity restored following treatment with 150 mg CQ daily for at least 30 months \[[@ref47], [@ref48]\]. The same research group reported *in vitro* and *ex vivo* data showing that autophagy inhibition was able to improve the response to BRAF inhibition in resistant tumour cells \[[@ref48]\]. Next, CQ was administered to two patients with acquired resistance to BRAF inhibition. The first patient was treated with standard doses of vemurafenib plus 250 mg daily of CQ during focal radiation of large primary lesions. Vemurafenib was continued and the CQ dose was increased to 500 mg daily after completion of radiation. A rapid favourable clinical response to the combination therapy was observed in as little as six weeks and was maintained for seven months, at which point the patient had to stop therapy for unrelated medical issues. The second patient was treated with 500 mg CQ daily in combination with standard dosing of vemurafenib. Acquired resistance to vemurafenib was overcome within four weeks of the addition of CQ and clinical improvement could be observed, which was maintained for two and a half months. However, therapy had to be stopped and the family chose to pursue palliative therapy afterwards.

### Multiple myeloma

Eleven patients with relapsed and refractory multiple myeloma were enrolled and treated with 500 mg CQ daily (on days 1--14 and 22--35) in addition to bortezomib and cyclophosphamide (administered orally twice daily) in a phase-2 clinical trial \[[@ref49]\]. Of these eleven patients, only eight patients were evaluable. CQ was able to partially restore the bortezomib sensitivity: three patients had a partial response, one had stable disease and four had progression as best responses.

The adjuvant therapeutic effect of 250 mg CQ twice daily in combination with cyclophosphamide and prednisone was tested for a period of ten days in 38 myeloma patients \[[@ref50]\]. Twenty patients received cyclophosphamide and prednisone, while the other 18 patients received extra treatment with CQ and caffeine, but no additional response was observed in the CQ-treated patient group.

HCQ
---

### Solid cancers

The effect of HCQ and temsirolimus combination therapy was tested in 27 patients with advanced solid cancer during a phase-1 dose-escalating study and subsequently in 13 patients with metastatic melanoma at the phase-2 recommended dose \[[@ref51]\]. No patient experienced an objective response but 19 out of the 27 phase-1 patients (73%) and 9 out of 13 melanoma patients (69%) had stable disease. In patients with stable disease, HCQ addition was shown to produce metabolic stress in the tumours. Inhibition of autophagy (see section on mechanisms of action), measured by counting the number of autophagic vacuoles per cell in tumour tissues and peripheral blood mononuclear cells of patients, was only noted in patients receiving at least 1200 mg HCQ daily. This study recommends an adjuvant HCQ dose of 600 mg, twice daily.

Next, the combinatory effect of HCQ and temozolomide was investigated in 40 cancer patients with advanced solid tumours and melanoma, and the recommended dose of 600 mg twice daily was confirmed \[[@ref52]\]. HCQ was shown to successfully inhibit autophagy, as evidenced by the significant accumulation of autophagic vacuoles in peripheral blood mononuclear cells (mean autophagic vacuole counts: 2.19 at baseline, 2.45 after HCQ treatment, 3.84 after treatment with HCQ plus TMZ \[difference between HCQ plus TMZ and baseline: *p* = 0.0007, difference between HCQ plus TMZ and HCQ only: *p* = 0.0034\]).

The safety and preliminary efficacy of HCQ and vorinostat combination treatment was tested during a phase-1 study in 27 patients with advanced solid tumours \[[@ref53]\]. In this study, the maximum-tolerated HCQ dose was set at 600 mg daily in combination with 400-mg vorinostat. A confirmed durable partial response was observed in a renal cell carcinoma patient, and prolonged stable disease was seen in two colorectal cancer patients. In contrast to the previous study, autophagy was not significantly affected.

Finally, in a pilot retrospective study, 25 stage-IV cancer patients (various types) who had no clinical response to maximally tolerated chemotherapy and to first-line metronomic chemotherapy were treated with sirolimus (2 mg/day) and the autophagy inhibitor HCQ (400 mg/day) in addition to their current metronomic chemotherapy for at least three months. The therapy was reported to be relatively safe, and the overall response rate was 40%, with an 84% disease control rate \[[@ref54]\]. However, this was a retrospective analysis requiring cautious interpretation.

### Glioblastoma

The efficacy and safety of HCQ was studied in combination with radiotherapy and temozolomide in 92 GBM patients during a phase-1--2 study \[[@ref55]\]. This study indicated a maximum tolerated dose (MTD) of 600 mg HCQ a day in this therapeutic setting. OS did not seem to be affected in comparison with the temozolomide arm of the trial reported by Stupp \[[@ref56]\], and autophagy was not found to be consistently inhibited in all patients.

### Lung cancer

The combination of HCQ with erlotinib can be used safely in daily doses of 150 mg erlotinib and 1000 mg HCQ, as determined by a phase-1 study in 27 patients with advanced non-small cell lung cancer (NSCLC) \[[@ref57]\]. Of the 19 patients who remained in the study, one had a partial response and four had stable disease as best response. Subsequent ophthalmic surveillance on seven trial participants who had taken HCQ for a duration longer than six months showed that retinal toxicity occurred in two patients after 11 and 17 months of exposure \[[@ref58]\].

This highlights the importance of retinal toxicity monitoring (via high-resolution spectral-domain optical coherence tomography, fundus auto fluorescence imaging, Humphrey visual field testing and multifocal electroretinography) during clinical trials with HCQ.

### Multiple myeloma

During a phase-1 study, the safety of the combination of HCQ and bortezomib was explored in 25 patients with relapsed or refractory myeloma \[[@ref59]\]. A dose of 600 mg HCQ twice daily was reported to be safe and tolerable in combination with standard doses of bortezomib. The increase in the number of autophagic vacuoles was not significantly associated with clinical response or HCQ exposure. Of 22 evaluable patients, three (14%) had very good partial responses, three (14%) had minor responses, ten (45%) had stable disease for at least one cycle and six (27%) had immediate progression.

### Pancreatic cancer

The safety of the combination of pre-operative HCQ (1200 mg daily) and gemcitabine administration was demonstrated in 35 patients with pancreatic adenocarcinoma in a phase-1--2 trial \[[@ref60]\]. This study reported promising clinical response markers (e.g. CA 19--9 biomarker and R0 resection rate). An exploratory analysis showed significantly improved disease-free survival and OS (15.03 versus 6.9 months and 34.83 versus 10.83 months, respectively) in patients for whom autophagy was sufficiently inhibited (*n* = 8) (at least 51% increase in the autophagy marker LC3B-II in peripheral blood mononuclear cells) compared with other patients (*n* = 9).

Next, a phase-2 study investigated the safety and efficacy of HCQ monotherapy with either 400 or 600 mg two times a day in 20 patients with previously treated metastatic pancreatic cancer, but no significant differences were observed between groups \[[@ref61]\]. In addition, inhibition of autophagy could not be achieved consistently, as shown by LC3B-II analysis in the lymphocytes of patients, and the two-month progression-free survival rate was only 10%.

### Sarcoma

The combination of 1 mg sirolimus and 200 mg HCQ twice daily for two weeks was tested in ten sarcoma patients who had failed first-line treatment \[[@ref62]\]. This study started from the hypothesis that there is metabolic symbiotic relationship between cancer-associated fibroblasts (CAFs) and sarcoma cells (see mechanisms of action). The study showed that this relationship might be altered by treatment with sirolimus and HCQ as glycolysis was inhibited within the tumours. Based on FDG PET response criteria, two weeks after treatment initiation, six patients showed partial response, three had stable disease and one had progressive disease. However, most patients discontinued treatment before the initially planned eight-week response assessment, for disease progression.

Mechanism of action
===================

Multiple hypotheses have been proposed on how CQ and HCQ exert their anti-cancer activity. Most studies reported the direct action of these drugs on cancer cells, but more recent studies have also mentioned important effects of CQ and HCQ on the tumour microenvironment. Based on preclinical studies, it is safe to say that CQ and HCQ have multiple mechanisms of action that might complement each other.

The most relevant and evidence-based mechanisms of action of CQ and HCQ in anti-cancer treatment will be briefly explained in the next section. The benefits of combining these antimalarial drugs with existing anti-cancer treatments will also be described. In the final section, the variation in sensitivity of cancer patients to CQ and HCQ therapy will be clarified.

Direct anti-tumour effects
--------------------------

The main and most studied anti-cancer effect of CQ and HCQ is the inhibition of autophagy, but other preclinically proven anti-cancer activities of the antimalarial agents include influencing the TLR9/nuclear factor kappa B (NF-κB) signalling pathway, the CXCL12/CXCR4 signalling pathway and the p53 pathway.

### Autophagy inhibition

Autophagy literally means 'self-eating'. It is a process in which a cell destroys old or defective cellular components, thereby releasing cellular building blocks including nucleotides, amino acids and fatty acids. Those degradation products can later be recycled by the cell to meet its metabolic needs. Autophagy is an essential intracellular process to ensure cell survival under stressful conditions (e.g. hypoxia, starvation and organelle damage). Different types of autophagy exist but, here, we will use the term to refer to macroautophagy. Autophagy is a complex multi-faceted process \[[@ref63]\]. One putative biomarker is the level of LC3B-II, an essential protein during autophagosome formation and the level of scaffolding protein p62 \[or sequestosome 1 (SQSTM1)\] \[[@ref64], [@ref65]\]. Autophagy has both pro-tumour and anti-tumour functions, which may be both stage and tissue-type specific.

In early carcinogenesis, autophagy has a tumour suppressive role since it has an important quality control function and protects the cell by sequestering and eliminating defective cellular components, such as damaged mitochondria, and by maintaining cellular homeostasis \[[@ref66], [@ref67]\]. In addition, several autophagic proteins can directly suppress tumour formation (e.g. Beclin-1, UVRAG and Bif-1) and autophagy has been shown to degrade tumour promoting proteins as well (e.g. p62/SQSTM1) \[[@ref68]\]. In line, deregulation of autophagy has been repeatedly associated with human cancers \[[@ref67]\].

In contrast, autophagy can promote tumour growth in more advanced stages of cancer \[[@ref69]\]. Pro-survival autophagy is induced in response to a variety of stressful conditions including but not limited to, starvation, loss of proteostasis, organelle damage and hypoxia. Some anti-cancer treatments can also induce pro-survival autophagy. Autophagic properties such as nutrient recycling can support cancer cell survival. Moreover, key regulators of cell growth can be degraded and the DNA damage response can be suppressed through increased autophagy \[[@ref66]--[@ref68]\]. Therefore, inhibition of autophagy can be an interesting anti-cancer strategy when cancer cells start depending on autophagy for survival, a moment called the autophagic switch \[[@ref64], [@ref70]\].

CQ and HCQ inhibit the autophagic flux at a late stage ([Figure 1](#figure1){ref-type="fig"}): the fusion of the autophagosomes with the lysosomes and subsequent degradation of the autolysosome. Upon entering the lysosomes, CQ and HQ become protonated, which leads to their entrapment in acidic lysosomes and an increase in the lysosomal pH, which inhibits the lysosomal degradative enzymes \[[@ref71]\]. Loehberg *et al* \[[@ref72]\] suggested that CQ might also modulate autophagy by modifying the PI3K/Akt/mTOR pathway.

In summary, autophagy plays a dual role in cancer and the success of autophagy inhibition, using the late stage inhibitors CQ and HCQ, depends on the timing and context. Autophagy is an interesting therapeutic target after the autophagic switch. However, the autophagy dependency of the tumour cells and any combinatory therapies can influence the sensitivity to autophagy inhibition, which will be discussed later.

### Inhibition of the TLR9/nuclear factor kappa B signalling pathway

TLR9, a member of the Toll-like receptor family, is located in the endosomal compartment. This receptor recognises unmethylated single stranded DNA and is necessary for pathogen recognition and innate immune system activation. In cancer, expression and stimulation of TLR9 is linked with invasiveness, as shown in *in vitro* experiments \[[@ref73]--[@ref75]\]. Moreover, the expression levels of TLR9 are higher in hepatocellular carcinoma, oesophageal, lung, breast, gastric and prostate cancer cells as compared with adjacent noncancerous cells, and high expression is often linked with poor prognosis \[[@ref73]--[@ref76]\]. Because of this observation, it was suggested that TLR9 might be an appropriate anti-cancer target \[[@ref73], [@ref74], [@ref76]\].

The TLR9-mediated activation of the NF-κB signalling pathway and the associated enhanced expression of matrix metalloproteinase-2 (MMP-2), MMP-7 and cyclo-oxygenase 2 mRNA, all factors associated with tumour progression and migration, can explain the role of TLR9 in cancer \[[@ref73], [@ref74]\]. At first, CQ was thought to inhibit this pathway by inhibiting endosomal acidification. However, CQ most likely modifies the structure of the nucleic acids responsible for TLR activation to prevent binding to TLRs \[[@ref77]\]. An *in vitro* study also showed that invasion of brain cancer cells is hypoxia-induced through upregulation of TLR9 expression, which could be significantly inhibited by CQ \[[@ref78]\].

In contrast, low expression of TLR9 is reported to be associated with a poorer prognosis in patients with triple-negative breast cancer. CQ had a promising effect on tumour growth and invasiveness, independent of the TLR9 status in triple-negative breast cancer cells *in vitro*, but it did not reduce the growth of orthotopic triple-negative breast cancer tumours *in vivo* \[[@ref79], [@ref80]\].

### Inhibition of CXCL12/CXCR4 signalling

The interaction between the CXCR4 chemokine receptor and its ligand CXCL12 plays a major role in chemotaxis and adhesion of cells, and secretion of growth factors. In recent years, research has shown an association between CXCL12/CXCR4 signalling and cancer progression \[[@ref81], [@ref82]\]. This interaction is said to influence the invasive phenotype of pancreatic cancer for example.

In 2012, a CXCR4 small molecule antagonist (NSC56612), structurally resembling CQ and HCQ, was identified through *in silico* modelling of this receptor \[[@ref82]\]. Next, CQ and HCQ were tested via *in vitro* assays, in which they were found to suppress pancreatic cancer cell proliferation \[[@ref82], [@ref83]\]. Mechanistic studies have shown that CQ, at least, partially inhibits CXCL12/CXCR4 signalling, as demonstrated via reduced phosphorylation of the extracellular signal-regulated kinase (ERK) and the signal transducer and activator of transcription 3 (STAT3). Interestingly, CQ and HCQ can induce CXCR4 internalisation in cancer stem cells, making these cells less sensitive to CXCL12 signals \[[@ref83]\].

Furthermore, a study in a pancreatic cancer patient-derived xenograft model showed that CQ specifically targets highly aggressive cancer stem cells through inhibition of their self-renewal process. Thus, CQ could be useful to block cancer stem cell-metastasis and may be combined with other anti-cancer agents (e.g. gemcitabine) that target the bulk of the tumour \[[@ref83]\].

### Interference with the p53 pathway

The tumour suppressor protein p53 plays an essential role in maintaining an error-free genome and inducing cell death in case the damage is irretrievable. Therefore, it is a key protein in the prevention of tumour development \[84\].

Both *in vitro* and *in vivo* research has indicated that CQ can stabilise the p53 protein and activate the p53-dependent transcription of pro-apoptotic genes \[[@ref17], [@ref23], [@ref24], [@ref72], [@ref84], [@ref85]\]. Several hypotheses have been proposed to explain the underlying mechanism, but there is no definite answer yet. One of these hypotheses is that CQ intercalates in DNA, which leads to structural changes and thus induction of p53 \[[@ref17], [@ref85]\]. Moreover, the p53 activation by CQ might be mediated by the ataxia telangiectasia mutated protein, dependent on the cell type \[[@ref17], [@ref23], [@ref24]\]

There is also some discussion about the relationship between the p53 status and the effects of autophagy inhibition on cancer development. Several studies report an accelerated tumour development when autophagy is inhibited in mice without p53 \[[@ref35], [@ref86], [@ref87]\], but Yang *et al* \[[@ref88]\] showed that that inhibition of autophagy could still have beneficial effect in p53 mutant tumours. Other studies confirmed that CQ exerts anti-cancer effects independent of the p53 pathway and the p53 status \[[@ref88]--[@ref90]\]. Synergy between the p53-dependent and -independent mechanisms of CQ is likely \[[@ref17]\].

Recently, a p53-dependent mechanism was reported in which CQ induces tumour suppressor protein Par-4 secretion, triggering paracrine apoptosis of cancer cells and inhibition of tumour metastasis. This mechanism involves the CQ-dependent activation of p53 and the subsequent induction of Rab8b, which is necessary for transport of vesicles of Par-4 to the plasma membrane \[[@ref91]\].

Moreover, CQ might prevent degradation of a p53-related protein, called Bcl homology-3-only protein p53 upregulated modulator of apoptosis (PUMA), as shown in mice studies. CQ increased the levels of PUMA, without affecting p53 in these studies \[[@ref20], [@ref92]\].

### Other potential mechanisms of action

Additional mechanisms have been suggested, but they have not been studied to the same extent and will only be briefly described here.

In recent years, it has become clear that glutaminolysis plays an important role in metabolic processes associated with cancer cell proliferation and survival. Therefore, targeting glutaminolysis could provide novel approaches to improve cancer treatment \[[@ref93]\]. It was shown that CQ affects glutamate dehydrogenase activity \[[@ref94]--[@ref96]\], which could be a potential mechanism of action in anti-cancer treatment. The hypothesis of inhibiting metabolic processes using metformin and CQ is currently being tested in one clinical trial with patients with isocitrate dehydrogenase 1 and 2 (IDH1/2)-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma \[[@ref97]\].

CQ and HCQ can activate caspase-3 and modulate the Bcl-2/Bax ratio inducing apoptosis in CLL, B-cell CLL and glioblastoma cells \[[@ref17], [@ref89], [@ref98]--[@ref100]\]. CQ-mediated cell-cycle-arrest and apoptosis was observed in breast cancer cells and was associated with a decrease in protein levels/activity of polo-like kinase 1 (Plk-1), ERK1/2 Akt and cell division cycle 25C (CDC25C). The same study described induction of caspase-3-mediated spindle abnormalities and down regulation of the mitochondrial transmembrane potential by CQ \[[@ref101]\]. A decreased lung cancer cell growth after low CQ concentrations was ascribed to an increased lysosomal volume and a phosphatidylcholine-specific phospholipase C involvement (PC-PLC). Higher CQ concentrations still induce apoptosis and necrosis, but likely via different processes \[[@ref102]\].

Moreover, HCQ might affect acetylation status in the N-terminal lysines of histones H3 and H4, thus modulating cell growth and differentiation, as shown in human breast cancer cells \[[@ref103]\].

In addition, CQ might directly affect Hedgehog signalling. Under normal conditions, this is a quiescent pathway, but activation can cause tumorigenesis and maintains cancer stem cells. Anti-cancer treatment options targeting this specific pathway have been explored, but this has yielded little results so far \[[@ref104]\]. One study suggested that CQ might modulate protein levels of the Hedgehog signalling pathway (smoothened, patched and GLI1 proteins) \[[@ref83]\].

CQ can inhibit hypoxia-stimulated metastasis via modulation of hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor (VEGF), and epithelial mesenchymal transition (EMT) as shown in a cholangiocarcinoma cell line \[[@ref105]\].

In triple-negative breast cancer, CQ was shown to eliminate cancer stem cells through reduction of the expression of Janus-activated kinase 2 and DNA methyl transferase 1 \[[@ref106]\] or through induction of mitochondrial dysfunction, subsequently causing oxidative DNA damage and impaired repair of double-stranded DNA breaks \[[@ref107]\].

Of note, various studies showed growth inhibition of melanoma cells after CQ administration, but this inhibition was more pronounced in pigmented melanoma, which could be ascribed to CQ's high affinity for melanin \[[@ref108]\]. There is also some contradictory evidence about a potential link between Burkitt's lymphoma incidence and CQ administration \[[@ref109], [@ref110]\].

Modulation of tumour micro-environment
--------------------------------------

### Immunomodulation

An increasing level of research is addressing the essential role of the immune system in cancer development. Activating the immune system against cancer cells is becoming a promising therapeutic approach \[[@ref111]\], as immune cells have the ability to detect and destroy malignant cells \[[@ref66]\].

Interestingly, autophagy and lysosomal function have been found to be involved in both innate and adaptive immunity \[[@ref66]\]. Therefore, inhibitors of these processes such as CQ and HCQ could potentially modulate the immune system and subsequently influence tumour development. However, lysosomal function and autophagy have a dual role in the anti-tumour immune response. Activation of these processes could both activate and impair the immune response, dependent on the circumstances \[[@ref66]\]. In addition, autophagy and lysosomal function affect the response of tumour cells to the immune system as well. For example, tumour cell autophagy can generate mediators that provoke an immune response via modulation of the tumour cell secretome and surface proteome, but it may also help tumour cells to escape the immune system \[[@ref64], [@ref66]\].

In general, the interaction between cancer cells and the immune system is complex and further research is warranted to determine when CQ or HCQ administration can lead to beneficial effects in the context of anti-tumour immunity \[[@ref112]\]. This is particularly important if CQ or HCQ would be considered for use in combination with immunomodulation anti-cancer therapies.

### Normalisation of the tumour vasculature

The tumour vasculature, responsible for supplying the tumour with nutrients and oxygen, is an important component in the tumour micro-environment and plays an essential role in tumour cell metastasis \[[@ref113]\]. A first therapeutic approach is to destroy blood vessels in order to block the nutrient and oxygen supply to the tumour. However, accumulating evidence suggests that improving the highly abnormal tumour vessel structure, also called vessel normalisation, is preferred over anti-angiogenic therapy. The benefits of vessel normalisation include a decrease in tumour hypoxia, reduced cancer cell intravasation and metastasis, and an increase in chemotherapeutic drug delivery and response \[[@ref114], [@ref115]\].

A recent study showed that CQ normalises tumour vessels, independent of its autophagy inhibitory effect, through reduction of vessel density and improvement of cell alignment and formation of tight junctions. At the molecular level, CQ alters endosomal Notch1 trafficking and signalling in endothelial cells, hereby increasing the quiescent phenotype of the endothelial cells \[[@ref26], [@ref116]\]. Of note, systemic CQ administration has also been shown to reduce the vascular toxicity of the intratumorally administered, anti-tumour agent Transferrin-CRM107 in *in vivo* glioma models \[[@ref117]\].

### Disruption of the CAF---cancer cell interplay

The final interplay between the tumour and its microenvironment that may be influenced by CQ involves CAFs \[[@ref118]\]. Glutamine and caveolin-1 are key players in this autophagy-mediated interplay, in which CAFs and tumour cells support each other through glutamine production/secretion and autophagy stimulation. Interestingly, this interplay can be uncoupled through the autophagy inhibitory or lysosomotropic activity of CQ, but the exact mechanism should still be clarified \[[@ref119], [@ref120]\].

Synergism with approved anti-cancer drugs
-----------------------------------------

Existing anti-cancer therapies often induce pro-survival autophagy in cancer cells, which is associated with therapeutic resistance. Because of their ability to inhibit autophagy, CQ and HCQ are able to sensitise tumour cells to chemotherapy and radiation. Therefore, these drugs are often tested in (pre)clinical research in combination with other anti-cancer therapies. Though, some caution is advised when concomitantly using these antimalarial drugs with other anti-cancer agents because autophagy can also be inhibited in normal cells, which causes unwanted toxicity (e.g. nephrotoxicity) \[[@ref121]\].

CQ-mediated sensitisation to anti-cancer therapy has also been ascribed to autophagy-independent mechanisms. As mentioned earlier, chemotherapeutics can reach the tumour site more easily after tumour vessel normalisation \[[@ref26], [@ref116]\]. Moreover, CQ can prevent the entrapment of protonated chemotherapeutic drugs by buffering the extracellular tumour environment and intracellular acidic spaces \[[@ref112]\]. For example, CQ can reduce the endosomal sequestration of certain drugs by raising the endosomal pH and, thus, increase their efficacy (e.g. doxorubicin, daunorubicin and mitoxantrone) \[[@ref122]--[@ref124]\]. Vezmar *et al* \[[@ref125], [@ref126]\] suggested that CQ influences multidrug resistance protein-mediated doxorubicin resistance by binding the multidrug resistance protein.

Prediction of efficacy in individual patients
---------------------------------------------

Autophagy dependency and metabolic stress levels of tumour cells vary widely depending on the tumour type and progression stage. Therefore, reliable measurements to predict tumour sensitivity to autophagy inhibition would be extremely useful for patient selection in clinical practice \[[@ref67]\]. As mentioned earlier, the status of tumour suppressor p53 can affect CQ efficacy, but other CQ sensitivity indicators have been identified as well.

First, EGFR overexpressing tumour cells, high levels of STAT3 activity, loss of caveolin-1, Akt- and Myc- driven tumour cells, and argininosuccinate synthetase enzyme deficiency are all associated with a high autophagy dependency and are therefore more sensitive to CQ administration \[[@ref16], [@ref28], [@ref119], [@ref127]--[@ref129]\]. Next, there is still discussion about the effect of the oncogenic BRAF (V600E) mutation on autophagy dependency of tumour cells \[[@ref47], [@ref130], [@ref131]\]. In addition, evidence has shown that autophagy is induced by the tumour suppressor alternative reading frame, but it should still be clarified whether this is cytotoxic or protective autophagy before we can determine whether CQ administration would exert beneficial effects \[[@ref132]\]. Moreover, oncogenic Ras, and especially Kras, mutation has also been suggested as an indicator of autophagy dependency and susceptibility to CQ \[[@ref27], [@ref133]\], but two other studies have reported that this mutation is not a reliable indicator \[[@ref134], [@ref135]\]. As mentioned earlier, however, HCQ has been shown to promote tumour growth in Ras-driven pancreatic tumours developing without p53 (Kras^G12D/+^ p53^--/--^) \[[@ref35], [@ref36]\]*.* Cells with the IDH1/2 mutations are metabolically vulnerable to CQ treatment, because they depend on glutaminolysis and autophagy, which is inhibited by CQ \[[@ref97]\].

Autophagy dependency is higher in case of nutritional stress, as shown in mesothelioma cells \[[@ref128]\], and neuroendocrine lung tumour cells are more sensitive to autophagy inhibition than non-neuroendocrine lung tumour cells \[[@ref136]\].

Finally, an *in vitro* study in four human glioma cell lines observed that higher steady-state mitochondrial membrane potential values, representing mitochondrial stability, can predict cancer cell resistance to CQ treatment \[[@ref137]\].

Our take
========

The final goal of this literature review was to inform further research and trials on repurposing CQ and HCQ as anti-cancer agents, as done previously for other agents \[[@ref138]\]. In addition, the ideal dose, route of administration, and therapeutic schedule that should be applied in anti-cancer therapy was explored. Finally, the potential difference in efficacy and toxicity between CQ and HCQ has been investigated.

Efficacy of CQ and HCQ in anti-cancer therapy
---------------------------------------------

The vast majority of preclinical studies on the effect of CQ monotherapy in cancer have reported a positive therapeutic effect, but the study parameters, doses, animal models and tumour types differ strongly between studies, complicating the interpretation of the results. Preclinical studies investigating the effect of HCQ in cancer are limited. Therefore, follow-up *in vivo* studies are warranted. A risk of publication bias exists so we cannot guarantee that all negative results have been reported.

Combination therapy with CQ or HCQ and existing anti-cancer therapies has been extensively studied in preclinical research, both *in vitro* and *in vivo*. The majority of these studies have reported an improved therapeutic efficacy as compared with monotherapy with existing anti-cancer drugs. Most studies hypothesise that CQ and HCQ could increase the efficacy of other anti-cancer drugs by blocking pro-survival autophagy. Because not all studies measured autophagy levels *in vivo,* it is difficult to determine to what extent the other proposed mechanisms play a role. [Table 2](#table2){ref-type="table"} is limited to studies that tested CQ or HCQ in combination with conventional anti-cancer agents *in vivo*, but there are many other combinations that have only been tested *in vitro*.

Finally, multiple clinical trials have investigated, or are going to investigate, the use of CQ and HCQ in different cancer types, always in combination with other anti-cancer drugs. The availability of clinical results is limited now, as most trials are still recruiting or ongoing, and those that have been completed focused primarily on safety and tolerability of CQ and HCQ in cancer. In short, these drugs have been found safe and tolerable in all completed studies and the anti-cancer effect of both compounds is promising. However, as many clinical trials are still ongoing, a definite conclusion on the repurposing intent of CQ and HCQ in anti-cancer therapy is pending. Still, data from first clinical trials and additional preclinical data point to a potential positive implementation of these drugs in anti-cancer treatment.

Doses, route of administration and therapeutic schedule
-------------------------------------------------------

In preclinical experiments, varying CQ and HCQ doses have been used, but most of the applied doses can be extrapolated to human doses. However, whether the dose to achieve autophagy inhibition, induction of apoptosis and tumour normalisation is achievable in humans remains an open question that would require collecting additional data in humans \[[@ref112]\]. Clinical trials have shown that daily doses between 150 and 500 mg for CQ and daily doses between 400 and 1200 mg for HCQ are safe and well tolerated, but two studies identified 600-mg HCQ daily as the MTD. HCQ is often administered twice daily to limit plasma fluctuations and toxicity. Of note, Pascolo recommended 10 mg/kg as the maximum realistic clinical dosage of CQ, but the recommended dose and MTD of CQ and HCQ might vary dependent on the tumour type and the concomitantly administered anti-cancer treatments.

Pascolo also suggests that timing of administration is of great importance. CQ must be administered after chemotherapy and not before, which is supported by data in a mouse model of colorectal cancer treated with gemcitabine \[[@ref139]\].

CQ or HCQ?
----------

HCQ has been reported to have less side effects than CQ (e.g. less risk of retinal toxicity) \[[@ref9], [@ref140], [@ref141]\], so it can be administered in higher doses for human use. Currently it is not clear yet whether there are differences in anti-cancer treatment efficacy between CQ and HCQ. The clinical trials that have already been completed suggest that CQ might be more efficacious than HCQ. However, no comparative clinical trial has been set up to confirm this hypothesis.

Yet, based on chemical structure, the altered safety and efficacy can be ascribed to the additional hydroxyl group in HCQ, causing pharmacokinetic differences that are essential for the working mechanism of the drugs (e.g. pKa alteration leading to differences in biprotonation and distribution) \[[@ref14], [@ref140]\].

Next steps
----------

More than 30 clinical trials are currently ongoing (Feb 2017). The results of these trials may indicate which tumour types are most sensitive to CQ and HCQ treatment, and which combination therapies can be beneficial. Additional preclinical studies could further characterise the most relevant mechanisms of action and their individual importance in anti-cancer therapy. Finally, CQ analogues and other more specific autophagy inhibitory agents are also under investigation for the treatment of cancer patients (e.g. Lys05) \[[@ref142]--[@ref146]\].

Conclusion
==========

CQ and HCQ have been studied in multiple preclinical cancer models and have demonstrated activity on several cancer-supporting pathways and in combination with a broad range of other therapies. Our review has highlighted the interesting multi-faceted actions of CQ and HCQ against cancer, making these drugs attractive for this complex disease \[[@ref147], [@ref148]\].

Even though it is too soon to make definite conclusions about the overall effect of CQ and HCQ in anti-cancer treatments, the clinical data already available are encouraging to further explore their potential as anti-cancer agents, with a preference for CQ. Until now, most clinical evidence was found in patients with glioblastoma and brain metastases and in patients with BRAF mutations, but some promising effects have been reported in patients with lung cancer, multiple myeloma and sarcoma as well. Although the side effects of CQ and HCQ are minor in comparison with conventional anti-cancer therapy, the possibility of retinal toxicity in trials planning long-term CQ and HCQ exposure requires the implementation of ophthalmologic monitoring. More than 30 clinical studies are currently evaluating HCQ and CQ in different cancers, most of them with the rationale to increase the efficacy of other anti-cancer therapies through inhibition of treatment-induced autophagy. The first clinical trials with CQ and HCQ have focused on the toxicity of different CQ doses in multiple populations and new trials should now focus on rigorous evaluation of efficacy.
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###### *In vivo* studies investigating the efficacy of CQ and HCQ monotherapy.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                         Animal model                                                                                                                                                                                                                                                              Tumour type                                                                                                             Animal (H)CQ dose                                                                      HED\[[@ref149]\]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- -----------------------------------------
  Jutten *et al* \[[@ref16]\]       NMRI-nu (nu/nu) female mice                                                                                                                                                                                                                                               Xenografts of U373-EGFRwt and U373 control cells                                                                        CQ: 60 mg/kg/day for seven consecutive days (IP)                                       292 mg/day

  Kim *et al* \[[@ref17]\]          NMRI nude mice                                                                                                                                                                                                                                                            Xenografts of U87MG cells                                                                                               CQ: Intracranial administration of 5μl with a concentration of 30 mM/day for 17 days   /

  Song *et al* \[[@ref18]\]         Male athymic BALB/c nu/nu mice                                                                                                                                                                                                                                            Xenografts of CD133+ and CD133- cells isolated from Huh 7 cells                                                         CQ: 60 mg/kg, twice weekly (IP)                                                        292 mg twice weekly

  Hu *et al* \[[@ref19]\]           Nude mice                                                                                                                                                                                                                                                                 Xenograft of HepG2-GFP\                                                                                                 CQ: 80 mg/kg twice daily, on a 3-day-on/2-day-off schedule for 25 days (SC)            398 mg twice daily (3 day-on/2 day-off)
                                                                                                                                                                                                                                                                                                              human liver\                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                              cancer cells                                                                                                                                                                                                   

  Lakhter *et al* \[[@ref20]\]      NOD-SCID mice                                                                                                                                                                                                                                                             Xenografts of SKMel23 cells                                                                                             CQ: 25 mg/kg, twice weekly for 3 weeks (IP)                                            122 mg twice weekly

  Zheng *et al* \[[@ref21]\]        Female BALB/c mice                                                                                                                                                                                                                                                        Transplantation of CT26 cells                                                                                           CQ: 50 or 25 mg/kg/day for 28 days (IP)                                                243 or 122 mg/day

  Jiang *et al* \[[@ref22]\]        Female BALB/c mice                                                                                                                                                                                                                                                        Transplantation of 4T1 mouse cells                                                                                      CQ: 50 or 25 mg/kg/day for 28 days (IP)                                                243 or 122 mg/day

  Loehberg *et al* \[[@ref23]\]     Wistar-Furth virgin female rats                                                                                                                                                                                                                                           NMU-induced mammary adenocarcinoma (IP, 50 mg/kg)                                                                       CQ: 3.5 mg/kg/week for 3 weeks (IP)                                                    34 mg/week

  Loehberg *et al* \[[@ref23]\]     BALB/c mice                                                                                                                                                                                                                                                               Transplantation of mammary ducts from 7- to 8-week-old p53-null BALB/c mice                                             CQ: 3.5 mg/kg/week for 8 weeks (IP)                                                    17 mg/week

  Maclean *et al* \[[@ref24]\]      ATM-null, p53-null mice (C57BL/6J) or Eμ-Myc transgenic mice (C57BL/6J)                                                                                                                                                                                                   Lymphoma                                                                                                                CQ: 3.5 mg/kg, every 5 days (combined oral/IP or IP alone)                             17 mg every 5 days

  Sun *et al* \[[@ref25]\]          Male Sprague Dawley rats                                                                                                                                                                                                                                                  DEN-induced hepatocarcinoma                                                                                             CQ: 50 mg/kg, every 3 days during week 0 to 9 or during week 10 to 17 (IP)             486 mg every 3 days

  Maes *et al* \[[@ref26]\]         Immunocompetent syngeneic (C57/Bl6) or immunodeficient(nu/nu) mice                                                                                                                                                                                                        Xenografts of A375m and transplantation of B16-F10 mouse cells                                                          CQ: 50 or 100 mg/kg/day (IP)                                                           243 or 486 mg/day

  Maycotte *et al* \[[@ref28]\]     Female Nude nu/nu mice                                                                                                                                                                                                                                                    Xenografts of MCF7 and MDAMB231 cells                                                                                   CQ: 60 mg/kg/day (IP)                                                                  292 mg/day

  Yang *et al* \[[@ref27]\]         NCr nude mice (Taconic)                                                                                                                                                                                                                                                   Xenografts of 8988T, H460 cells, and panc1 cells and an orthotopic PDAC model with 8988T cells grown in the pancreata   CQ: 60 mg/kg/day (IP)                                                                  292 mg/day

  Hiraki *et al* \[[@ref29]\]       Bashford cancer, Ehrlich ascites and solid cancer, MH134 tumour maintained in inbred strains Strong A, C3H, RIll, and RF mice, Yoshida ascites and solid tumours carried in Wistar and random-bred rats, and Brown-Pearce carcinoma transplanted in albino male rabbits   CQ: 6 - 15 mg/kg/day (IP, IV, SC, oral)                                                                                 58 -- 292 mg/day                                                                       

  Pellegrini *et al* \[[@ref30]\]   Female NMRI nu/nu mice                                                                                                                                                                                                                                                    Xenografts of HCT116 and HT29 cells                                                                                     CQ: 20 mg/kg, every 2 days for 16 days (IP)                                            97 mg every 2 days

  Dutta *et al* \[[@ref32]\]        Female inbred F344 rats                                                                                                                                                                                                                                                   Transplantation of R3230AC mammary adenocarcinoma                                                                       CQ: 45 mg/kg, 5 days a week for 25 days (IP)                                           438 mg 5 days a week

  Yamaguchi *et al* \[[@ref33]\]    Adult female C3H/HeN mice and adult male dd-mice                                                                                                                                                                                                                          Transplantation of spontaneous C3H mammary carcinoma, Bashford carcinoma 63 and Ehrlich ascites tumours                 CQ: 0.2 mg/2 days for 12 days (IP)                                                     /

  Chi *et al* \[[@ref34]\]          Transgenic flies (Drosophila)                                                                                                                                                                                                                                             RasV12 tumours                                                                                                          CQ- containing medium (final concentration: 1 mg/ml)                                   /

  Rosenfeldt *et al* \[[@ref35]\]   KrasG12D/-p53-/- and KrasG12D/-p53+/+ mice                                                                                                                                                                                                                                Pancreatic ductal adenocarcinoma                                                                                        HCQ: 60 mg/kg/day (IP)                                                                 292 mg/day
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CQ (chloroquine), HCQ (hydroxychloroquine), EGFR (epidermal growth factor receptor), IP (intraperitoneal), NOD SCID mice (non-obese diabetic, severe combined immunodeficiency mice), NMU (N-methyl-N-nitrosourea), ATM (ataxia telangiectasia mutated), DEN (diethylnitrosamine), IV (intravenous), SC (subcutaneous), HED (Human Equivalent Dose).

###### Overview of *in vivo* research combining known anti-cancer agents with either CQ or HCQ.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                 (H)CQ   Intervention              Animal model                                                         Tumour type                                                                                                  Therapeutic effect of combination therapy
  ----------------------------------------- ------- ------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Golden *et al* \[[@ref150]\]              CQ      Temozolomide (TMZ)        4- to 6-week-old male athymic nu/nu mice                             U87MG glioma cells                                                                                           Higher levels of the proapoptotic protein C/EBP homologous protein/growth arrest- and DNA damage-inducible gene 153 (CHOP/GADD-153)

  Zanotto-Filho *et al* \[[@ref151]\]       CQ      TMZ\                      8-week-old male wistar rats                                          C6 brain cells                                                                                               Autophagy inhibition and significantly reduced tumour growth
                                                    (+curcumin)                                                                                                                                                                                                 

  Gaudin *et al* \[[@ref152]\]              CQ      Cyclophosphamide\         Golden Syrian hamster                                                Melanoma and plasmacytoma                                                                                    Sensitisation to cyclophosphamide
                                                    (Cytoxan)                                                                                                                                                                                                   

  Lefort *et al* \[[@ref153]\]              CQ      Cyclophosphamide\         6-week-old female Swiss nude mice                                    MDA-MB-231 human breast cancer cells                                                                         Significant tumour growth inhibition and reduction of lung metastases
                                                    (+Adriamycin)                                                                                                                                                                                               

  Amaravadi *et al* \[[@ref129]\]           CQ      Cyclophosphamide          8-to-10-week-old C57BL/6 ×129F1 mice                                 Myc/p53ERTAM lymphomas                                                                                       Tumour growth inhibition and significant delay of tumour recurrence

  Yu *et al* \[[@ref154]\]                  CQ      Cisplatin                 4-to-6-week-old female BALB/c nu/nu mice                             EC109/CDDP human oesophageal cells                                                                           Significantly lower tumour growth rate

  Zhang *et al* \[[@ref155]\]               CQ      Cisplatin                 8-week-old female BALB/c mice                                        SGC7901 human gastric cancer cells                                                                           Significantly reduced tumour volume and weight

  Zhao*et al* \[[@ref156]\]                 CQ      Cisplatin                 5-to-6-week-old BALB/c nude mice                                     FaDu human hypopharyngeal cells                                                                              Prolonged survival

  Ding *et al* \[[@ref157]\]                CQ      Oxaliplatin               4-week-old male athymic BALB/c nude mice                             Huh7 hepatocarcinoma cells                                                                                   Significantly reduced tumour volume

  Selvakumaran *et al* \[[@ref158]\]        CQ      Oxaliplatin\              8-to-10-week-old female C.B.17 SCID mice                             HT29 human colon carcinoma cells                                                                             Significant tumour growth delay
                                                    (+bevacizumab)                                                                                                                                                                                              

  Liang *et al* \[[@ref107]\]               CQ      Carboplatin               immunodeficient SCID-Beige mice                                      SUM159 cells breast cancer cells (orthotopic)                                                                Significantly reduced tumour growth, decreased mitochondrial metabolic activity, decreased cell viability and increased levels of LC3b-II and p62

  Balic *et al* \[[@ref83]\]                CQ      Gemcitabine               Immuno-compromised mice                                              patient- derived PDAC tumour tissues                                                                         Effective tumour elimination and improved overall survival

  Shoemaker *et al* \[[@ref159]\]           CQ      5-FU                      Young adult female C3H mice                                          C3HBA mammary carcinoma                                                                                      Significantly reduced tumour size

  Guo *et al* \[[@ref160]\]                 CQ      5-FU                      5-week-old male athymic BALB/c nu/nu mice                            SMMC-7721 hepatocarcinoma cells                                                                              Significantly reduced tumour volume and weight and significantly higher levels of apoptosis

  Sasaki *et al* \[[@ref161]\]              CQ      5-FU                      6-week-old female BALB/c mice                                        Colon26 colon cancer cells                                                                                   Significantly increased inhibition of tumour growth and increased number of apoptotic cells and proapoptotic protein expression levels

  Shoemaker *et al* \[[@ref162]\]           CQ      5-FU\                     Adult female C3H/He mice                                             C3HBA breast cancer cells                                                                                    Significant tumour reduction
                                                    (+ 6-propyl-thiouracil)                                                                                                                                                                                     

  Xiong *et al* \[[@ref163]\]               CQ      Daunorubicin              Female DBA/2 mice on a folate-deficient diet                         L1210JF leukaemia cells                                                                                      No effect

  Arnold *et al* \[[@ref164]\]              CQ      Etoposide                 Female CBA/Ca mice                                                   TLX5 murine ascitic tumour cells                                                                             Significant improvement in increased life span

  Cook *et al* \[[@ref165]\]                HCQ     Tamoxifen and faslodex    5-week-old, intact, athymic nude mice                                Tamoxifen-resistant MCF7-RR and faslodex-resistant /Tamoxifen cross-resistant LCC9 ER+ breast cancer cells   Significantly reduced tumour size and tumour wet weight with HCQ and tamoxifen, no effect with faslodex and HCQ

  Loehberg *et al* \[[@ref72]\]             CQ      Everolimus                4-to-6-week-old, female NMRI nu/nu mice                              MCF7 breast cancer cells                                                                                     Significant tumour suppression

  Seront *et al* \[[@ref166]\]              CQ      Rapamycin                 8-week--old female NMRI nude mice                                    MDA-MB-231 and MCF-7 breast cancer cells                                                                     Tumour growth reduction in mice implanted with large, hypoxic mammary tumours (not in smaller tumours)

  Bray *et al* \[[@ref167]\]                CQ      Temsirolimus              nude mice                                                            RCC4 renal carcinoma cells                                                                                   Significantly reduced tumour growth

  Kaneko *et al* \[[@ref168]\]              CQ      Temsirolimus              4-to-6-week-old BALB/c nu/nu and BALB/c mice                         CaR-1, HT-29, colon26 colon cancer cells                                                                     Significantly reduced tumour growth

  Xie *et al* \[[@ref169]\]                 HCQ     Temsirolimus              6-week-old male nude NCr Nu-M mice                                   UACC903 melanoma cells                                                                                       Significantly tumour suppression and slower tumour growth

  Rao *et al* \[[@ref170]\]                 CQ      Panobinostat              NOD/SCID mice                                                        MB-231-luciferase mammary cells                                                                              Slight additional decrease in tumour growth as compared to CQ or Panobinostat monotherapy, but significant increase in survival time

  Carew *et al* \[[@ref171]\]               CQ      Vorinostat                Female nude BALB/c mice                                              HCT8 colon cancer cells                                                                                      Significantly enhanced tumour reduction

  Ding *et al* \[[@ref172]\]                CQ      Bortezomib                6-to-8-week-old female BALB/c mice                                   HCT116 colon cancer cells                                                                                    Significant inhibition of tumour growth and higher levels of apoptosis

  Hui *et al* \[[@ref173]\]                 CQ      Bortezomib                nude mice                                                            MHCC-97H and Huh-7 hepatocarcinoma tissues                                                                   Significantly reduced tumour growth and increased apoptosis

  Tang *et al* \[[@ref174]\]                CQ      Gefitinib                 6-week-old male BALB/c nude mice                                     PC-9/wt and PC-9/gefB4 lung cancer cells                                                                     Significantly reduced tumour growth

  Dragowska *et al* \[[@ref175]\]           HCQ     Gefitinib                 female Rag2M immune-compromised mice                                 JIMT-1 breast cancer cells                                                                                   58% tumour reduction

  Bokobza *et al* \[[@ref176]\]             CQ      Gefitinib\                BALB/c female nude mice                                              HCC-827 lung cancer cells                                                                                    Significantly inhibited tumour growth compared to the control, addition of Akt inhibitor or chloroquine to gefitinib increased anti-tumour effects, but was not found to be significant.
                                                    (+ Akt inhibitor)                                                                                                                                                                                           

  Zou *et al* \[[@ref177]\]                 HCQ     Erlotinib                 5-to-6-week-old athymic nude mice                                    H358 or H460 human NSCLC cells                                                                               Significant sensitisation to erlotinib therapy

  Bellodi *et al* \[[@ref178]\]             CQ      Imatinib                  Sub-lethally irradiated C3H/HeJ mice                                 MigRI GFP-LC3b--transduced 32D-p210BCR/ABL cells                                                             Significant sensitisation to imatinib therapy

  Abdel-Aziz *et al* \[[@ref179]\]          CQ      Sunitinib                 Female Swiss albino mice                                             Ehrlich ascites carcinoma cells                                                                              Significantly reduced tumour growth and weight

  Shimizu *et al* \[[@ref180]\]             CQ      Sorafenib                 BALB/c nude mice                                                     Huh7 hepato-carcinoma cells                                                                                  Significantly suppressed tumour growth

  Shi *et al* \[[@ref181]\]                 CQ      Sorafenib                 Male athymic BALB/c nude mice                                        MHCC97-L hepatocellular cells                                                                                Significantly reduced tumour growth and increased apoptosis

  Ji *et al* \[[@ref182]\]                  CQ      Crizotinib                6- to 7-week-old female CD-1 nude mice                               crizotinib-resistant H3122CR-1 lung cancer cells                                                             Sensitisation of drug resistant lung cancer cells to crizotinib

  You *et al* \[[@ref183]\]                 HCQ     Crizotinib                5-to-6-week-old female athymic BALB/c nude mice                      SPC-A1 human lung cancer cells                                                                               Significantly reduced tumour growth and increased apoptosis

  Mitou *et al* \[[@ref184]\]               CQ      Crizotinib                6-week-old female NOD-SCID mice                                      Karpas-299 lymphoma cells                                                                                    Significantly reduced tumour growth and increased apoptosis

  Shen *et al* \[[@ref185]\]                CQ      Vandetanib                6-to-8-week-old female BALB/c nude mice                              U251 glioblastoma cells                                                                                      Significantly reduced tumour growth and increased apoptosis

  Hu *et al* \[[@ref186]\]                  CQ      Bevacizumab               6-to-8-week-old female BALB/c nu/nu mice                             1\) GBM39 primary glioma cells\                                                                              Significantly suppressed GBM39, U87MG, G55, and patient specimen-derived SF8244 tumour growth
                                                                                                                                                   2) Subcutaneous U87MG glioma cells\                                                                          
                                                                                                                                                   3) G55 glioma cells\                                                                                         
                                                                                                                                                   4) patient-specimen derived SF8244 cells                                                                     

  Selvakumaran *et al* \[[@ref158]\]        CQ      Bevacizumab\              8-to-10-week-old female C.B.17 SCID mice                             HT29 human colon carcinoma cells                                                                             Significantly delayed tumour growth
                                                    (+ oxaliplatin)                                                                                                                                                                                             

  Cufi *et al* \[[@ref187]\]                CQ      Trastuzumab               4-to-5-week-old female athymic nude mice                             JIMT-1 breast cancer cells                                                                                   Significantly reduced tumour growth and increased Bax/Bcl-2 ratio

  Gaudin *et al* \[[@ref152]\]              CQ      Radiotherapy              Golden Syrian hamster                                                Melanoma and plasma cytoma                                                                                   Increased sensitivity of melanoma and plasma cytoma tumour cells to X-rays

  Ratikan *et al* \[[@ref188]\]             CQ      Radiotherapy              6-week-old female H-2 3H/Sed//Kam and H-2 Rag2-/-, gamma c -/-mice   MCaK breast cancer cells                                                                                     Significantly higher cure rate, delayed tumour growth and enhanced immunogenicity

  Wei *et al* \[[@ref189]\]                 CQ      PDT                       NOD/SCID mice                                                        PROM1/CD133+ colorectal cancer stem cells                                                                    Restoration of sensitivity to PDT

  Liang *et al* \[[@ref190]\]               CQ      HDIL-2                    8-to-10-week-old female C57BL/6 (B6, H-2b) mice                      luciferase-labeled mouse MC38 colorectal cancer cells                                                        Significantly reduced tumour growth and prolonged survival time

  Thomas *et al* \[[@ref191]\]              CQ      Nelfinavir\               Athymic mice                                                         MDA-MB-468 and MCF-7 breast cancer cells                                                                     Triple-drug treatment displayed obvious anti-cancer\
                                                    Celecoxib                                                                                                                                                                                                   effects in both TNBC (MDA-MB-468) and non-TNBC (MCF-7) xenograft (=proof of principle study, more extensive *in vivo* experiments needed)

  Harhaji-Trajkovic *et al* \[[@ref192]\]   CQ      Caloric restriction       5-to-6-week-old female C57BL/6 mice                                  B16 melanoma cells                                                                                           Combination of CQ and caloric restriction almost completely abolished B16 melanoma growth

  Thomas *et al* \[[@ref193]\]              CQ      Hyperthermia              male white Ajax mice                                                 C-1300 murine neuroblastoma                                                                                  ! Increased tumour growth and metastasis

  Gao *et al* \[[@ref194]\]                 CQ      TACE                      Adult New Zealand White rabbits                                      VX2 liver tumours                                                                                            Significantly reduced tumour volume and growth rate
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CQ (chloroquine), HCQ (hydroxychloroquine), SCID (severe combined immunodeficiency mice), PDAC (pancreatic ductal adenocarcinoma), 5-FU (5-fluorouracil) NOD (non-obese diabetic), wt (wild-type), PDT (photodynamic therapy), HDIL-2 (high-dose interleukin-2), TACE (transcatheter arterial chemoembolisation)

###### Information on clinical trials investigating CQ use in cancer (Source: ClinicalTrials.gov).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ClinicalTrials.gov ID   Type of cancer                                                                                                                                                                Intervention                                                        Study Phase    Location          Status                   First received   Last verified
  ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------- ----------------- ------------------------ ---------------- ---------------
  NCT00224978             GBM                                                                                                                                                                           CQ\                                                                 Phase 3        Mexico            Completed                Sept 2005        Nov 2009
                                                                                                                                                                                                        (+ conventional treatment)                                                                                                                     

  NCT01438177             Multiple myeloma                                                                                                                                                              CQ,\                                                                Phase 2        US                Completed, has results   Sept 2011        June 2016
                                                                                                                                                                                                        Velcade,\                                                                                                                                      
                                                                                                                                                                                                        Cyclophosphamide                                                                                                                               

  NCT01727531             Brain metastasis                                                                                                                                                              CQ,\                                                                Not provided   US                Completed                Nov 2012         Apr 2015
                                                                                                                                                                                                        Radiation therapy                                                                                                                              

  NCT01777477             Pancreatic cancer                                                                                                                                                             CQ,\                                                                Phase 1        Switzerland       Completed                Jan 2013         Sept 2015
                                                                                                                                                                                                        Gemcitabine                                                                                                                                    

  NCT01894633             Brain metastasis                                                                                                                                                              CQ,\                                                                Phase 2        Mexico            Terminated               June 2013        July 2013
                                                                                                                                                                                                        Radiotherapy                                                                                                                                   

  NCT01469455             Local metastatic melanoma                                                                                                                                                     CQ,\                                                                Phase 1        France            Completed                Oct 2011         June 2016
                                                                                                                                                                                                        DT01,\                                                                                                                                         
                                                                                                                                                                                                        Radiotherapy                                                                                                                                   

  NCT01023477             Ductal carcinoma in situ                                                                                                                                                      CQ\                                                                 Phase 1 - 2    US                Ongoing                  Dec 2009         Sept 2016
                                                                                                                                                                                                        (Procedure: breast biopsy)                                                                                                                     

  NCT00969306             Small cell lung cancer                                                                                                                                                        CQ                                                                  Phase 1        The Netherlands   Recruiting               Aug 2009         Feb 2016

  NCT01446016             Breast cancer                                                                                                                                                                 CQ,\                                                                Phase 2        US                Recruiting               Sept 2011        Sept 2016
                                                                                                                                                                                                        Taxane,\                                                                                                                                       
                                                                                                                                                                                                        Taxotere,\                                                                                                                                     
                                                                                                                                                                                                        Abraxane,\                                                                                                                                     
                                                                                                                                                                                                        Ixabepilone                                                                                                                                    

  NCT01575782             Small cell lung cancer                                                                                                                                                        CQ,\                                                                Phase 1        The Netherlands   Recruiting               Apr 2012         Sept 2016
                                                                                                                                                                                                        Radiotherapy                                                                                                                                   

  NCT02071537             Advanced solid tumours                                                                                                                                                        CQ,\                                                                Phase 1        US                Recruiting               Feb 2014         Dec 2015
                                                                                                                                                                                                        Carboplatin,\                                                                                                                                  
                                                                                                                                                                                                        Gemcitabine                                                                                                                                    

  NCT02333890             Breast cancer                                                                                                                                                                 CQ (and placebo)\                                                   Phase 2        Canada            Recruiting               Jan 2015         Nov 2016
                                                                                                                                                                                                        (prior to surgery)                                                                                                                             

  NCT02366884             Neoplasms                                                                                                                                                                     Anti-Bacterial Agents,\                                             Phase 2        Mexico            Recruiting               Feb 2015         Aug 2015
                                                                                                                                                                                                        Anti-Fungal Agents,\                                                                                                                           
                                                                                                                                                                                                        Anti-Protozoal Agents                                                                                                                          

  NCT02496741             Glioma,\                                                                                                                                                                      CQ,\                                                                Phase 1 - 2    The Netherlands   Recruiting               June 2015        Nov 2015
                          Cholangiocarcinoma,\                                                                                                                                                          Metformin                                                                                                                                      
                          Chondrosarcoma                                                                                                                                                                                                                                                                                                               

  NCT02378532             GBM                                                                                                                                                                           CQ,\                                                                Phase 1        The Netherlands   Recruiting               Feb 2015         Aug 2016
                                                                                                                                                                                                        Radiotherapy,\                                                                                                                                 
                                                                                                                                                                                                        Temozolomide                                                                                                                                   

  NCT02432417             Glioblastoma,\                                                                                                                                                                CQ,\                                                                Phase 2        Not provided      Not yet recruiting       Apr 2015         Apr 2016
                          Astrocytoma (Grade IV)                                                                                                                                                        Radiotherapy                                                                                                                                   

  NCT03243461             Glioblastoma WHO Grade IV, Diffuse Mid-line Glioma Histone 3 K27M, WHO Grade IV Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma, Gliomatosis Cerebri   Radiochemotherapy with Temozolomide, Valproic Acid or Chloroquine   Phase 3        Germany           Not yet recruiting       Aug 2017         Oct 2017
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Information on clinical trials investigating HCQ use in cancer (Source: ClinicalTrials.gov).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ClinicalTrials.gov ID   Type of cancer                                                Intervention                                  Study Phase      Location                      Status                    First received   Last verified
  ----------------------- ------------------------------------------------------------- --------------------------------------------- ---------------- ----------------------------- ------------------------- ---------------- ---------------
  NCT00765765             Breast cancer                                                 HCQ,\                                         Phase 1 - 2      US                            Terminated, has results   Oct 2008         Nov 2013
                                                                                        Ixabepilone                                                                                                                             

  NCT00786682             Prostate cancer                                               HCQ,\                                         Phase 2          US                            Terminated, has results   Nov 2008         Sept 2013
                                                                                        Docetaxel                                                                                                                               

  NCT00728845             Lung cancer                                                   HCQ,\                                         Phase 1 - 2      US                            Terminated, has results   Aug 2008         Sept 2013
                                                                                        Bevacizumab,\                                                                                                                           
                                                                                        Carboplatin,\                                                                                                                           
                                                                                        Paclitaxel                                                                                                                              

  NCT01026844             Non-small cell lung cancer                                    HCQ,\                                         Phase 1          US                            Terminated, has results   Dec 2009         June 2013
                                                                                        Erlotinib                                                                                                                               

  NCT01842594             Soft tissue sarcoma                                           HCQ,\                                         Phase 2          Taiwan                        Terminated, has results   Dec 2012         Oct 2015
                                                                                        Sirolimus                                                                                                                               

  NCT01144169             Renal cell carcinoma                                          HCQ\                                          Phase 1          US                            Terminated                June 2010        Oct 2016
                                                                                        (prior to surgery)                                                                                                                      

  NCT01417403             Bone metastases\                                              HCQ,\                                         Phase 1          US                            Terminated                Aug 2011         Feb 2015
                          unspecified adult solid tumour                                Radiation therapy                                                                                                                       

  NCT00771056             B-cell chronic lymphocytic leukaemia                          HCQ                                           Phase 2          US                            Terminated                Oct 2008         Aug 2016

  NCT00714181             Unspecified adult solid tumour                                HCQ,\                                         Phase 1          US                            Completed                 July 2008        Feb 2016
                                                                                        Temozolomide                                                                                                                            

  NCT01396200             Multiple myeloma                                              HCQ,\                                         Phase 0          US                            Completed                 July 2011        Feb 2013
                                                                                        Rapamycin,\                                                                                                                             
                                                                                        Cyclophosphamide,\                                                                                                                      
                                                                                        Dexamethasone                                                                                                                           

  NCT01634893             Refractory or relapsed solid tumours                          HCQ,\                                         Phase 1          US                            Completed                 July 2012        Mar 2016
                                                                                        Sorafenib                                                                                                                               

  NCT01828476             Prostate cancer                                               HCQ,\                                         Phase 2          US                            Completed                 Mar 2013         Mar 2016
                                                                                        Abiraterone,\                                                                                                                           
                                                                                        ABT-263                                                                                                                                 

  NCT01006369             Colorectal cancer                                             HCQ,\                                         Phase 2          US                            Suspended                 Oct 2009         Dec 2014
                                                                                        Bevacizumab,\                                                                                                                           
                                                                                        FOLFOX6,\                                                                                                                               
                                                                                        XELOX regimen\                                                                                                                          
                                                                                        (capecitabine,\                                                                                                                         
                                                                                        oxaliplatin)                                                                                                                            

  NCT00726596             Prostate cancer                                               HCQ                                           Phase 2          US                            Ongoing                   July 2008        Dec 2015

  NCT00813423             Adult solid neoplasm                                          HCQ,\                                         Phase 1          US                            Ongoing                   Dec 2008         Nov 2016
                                                                                        Sunitinib malate                                                                                                                        

  NCT00909831             Unspecified adult solid tumour                                HCQ,\                                         Phase 1          US                            Ongoing                   May 2009         Feb 2016
                                                                                        Temsirolimus                                                                                                                            

  NCT00962845             Melanoma                                                      HCQ (prior to surgery)                        Phase 0          US                            Ongoing                   Aug 2009         July 2016

  NCT00977470             Non-small cell lung cancer                                    HCQ,\                                         Phase 2          US                            Ongoing                   Sept 2009        Sept 2016
                                                                                        Erlotinib                                                                                                                               

  NCT01128296             Pancreatic cancer                                             HCQ,\                                         Phase 1 - 2      US                            Ongoing                   May 2010         Jan 2015
                                                                                        Gemcitabine (prior to surgery)                                                                                                          

  NCT01273805             Pancreatic cancer                                             HCQ                                           Phase 2          US                            Ongoing                   Jan 2011         Jan 2016

  NCT01480154             Advanced solid tumours, melanoma, prostate or kidney cancer   HCQ,\                                         Phase 1          US                            Ongoing                   Nov 2011         Feb 2016
                                                                                        Akt Inhibitor MK2206                                                                                                                    

  NCT01689987             Relapsed or refractory multiple myeloma                       HCQ,\                                         Phase 1          US                            Ongoing                   Sept 2012        Aug 2016
                                                                                        Cyclophosphamide,\                                                                                                                      
                                                                                        Dexamethasone,\                                                                                                                         
                                                                                        Sirolimus                                                                                                                               

  NCT01897116             Melanoma                                                      HCQ,\                                         Phase 1          US                            Ongoing                   June 2013        July 2016
                                                                                        Vemurafenib                                                                                                                             

  NCT02421575             Prostate cancer                                               HCQ (before prostatectomy or local therapy)   Phase 0          US                            Ongoing                   Dec 2014         July 2016

  NCT01494155             Pancreatic cancer                                             HCQ,\                                         Phase 2          US                            Ongoing                   July 2011        Sept 2016
                                                                                        Capecitabine,\                                                                                                                          
                                                                                        Radiation: Proton or Photon\                                                                                                            
                                                                                        Radiation Therapy                                                                                                                       

  NCT01602588             Glioblastoma                                                  HCQ,\                                         Phase 2          UK                            Ongoing                   May 2012         Nov 2016
                                                                                        Short Course radiotherapy                                                                                                               

  NCT02470468             Stage IV non-small cell lung cancer                           DCVAC,\                                       Phase 1 - 2      Czech Republic and Slovakia   Ongoing                   June 2015        Nov 2016
                                                                                        Standard of Care Chemotherapy\                                                                                                          
                                                                                        (Carboplatin,\                                                                                                                          
                                                                                        Paclitaxel),\                                                                                                                           
                                                                                        Immune enhancers (Interferon-α and HCQ)                                                                                                 

  NCT01023737             Malignant solid tumour                                        HCQ,\                                         Phase 1          US                            Recruiting                July 2009        Sept 2016
                                                                                        Vorinostat                                                                                                                              

  NCT01206530             Colorectal cancer                                             HCQ,\                                         Phase 1 - 2      US                            Recruiting                Sept 2010        Sept 2016
                                                                                        Oxaliplatin,\                                                                                                                           
                                                                                        Leucovorin,\                                                                                                                            
                                                                                        5-fluorouracil,\                                                                                                                        
                                                                                        Bevacizumab                                                                                                                             

  NCT01266057             Advanced cancers                                              HCQ,\                                         Phase 1          US                            Recruiting                Dec 2010         Nov 2016
                                                                                        Sirolimus,\                                                                                                                             
                                                                                        Vorinostat                                                                                                                              

  NCT01510119             Renal cell carcinoma                                          HCQ,\                                         Phase 1 - 2      US                            Recruiting                Jan 2012         Dec 2015
                                                                                        RAD001                                                                                                                                  

  NCT01506973             Advanced and metastatic adenocarcinoma                        HCQ,\                                         Phase 1 - 2      US                            Recruiting                Jan 2012         Sept 2016
                                                                                        Gemcitabine/abraxane                                                                                                                    

  NCT01550367             Metastatic renal cell carcinoma                               HCQ,\                                         Phase 1 - 2      US                            Recruiting                Feb 2012         May 2015
                                                                                        IL-2                                                                                                                                    

  NCT01649947             Non-small cell lung cancer                                    HCQ,\                                         Phase 2          US                            Recruiting                July 2012        July 2016
                                                                                        Paclitaxel,\                                                                                                                            
                                                                                        Carboplatin,\                                                                                                                           
                                                                                        Bevacizumab                                                                                                                             

  NCT01978184             Pancreatic cancer                                             HCQ,\                                         Phase 2          US                            Recruiting                Oct 2013         Dec 2015
                                                                                        Gemcitabine,\                                                                                                                           
                                                                                        Abraxane                                                                                                                                

  NCT02013778             Hepatocellular carcinoma                                      HCQ,\                                         Phase 1 - 2      US                            Recruiting                Dec 2013         Sept 2016
                                                                                        TACE                                                                                                                                    

  NCT02232243             Solid tumour                                                  HCQ (prior to surgery)                        Phase 1          US                            Recruiting                Sept 2014        Oct 2016

  NCT02257424             Advanced BRAF mutant melanoma                                 HCQ,\                                         Phase 1 - 2      US                            Recruiting                Oct 2014         June 2016
                                                                                        Dabrafenib,\                                                                                                                            
                                                                                        Trametinib                                                                                                                              

  NCT02316340             Colorectal cancer                                             HCQ,\                                         Phase 2          US                            Recruiting                Dec 2014         Sept 2016
                                                                                        Vorinostat,\                                                                                                                            
                                                                                        Regorafenib                                                                                                                             

  NCT02414776             Oestrogen receptor positive breast cancer                     HCQ,\                                         Phase 1 (1b/2)   US                            Recruiting                Jan 2015         Apr 2015
                                                                                        Hormonal therapy                                                                                                                        

  NCT02631252             Acute myeloid leukaemia                                       HCQ,\                                         Phase 1          US                            Not yet recruiting        Dec 2015         Dec 2015
                                                                                        Mitoxantrone,\                                                                                                                          
                                                                                        Etoposide                                                                                                                               

  NCT02722369             Small cell lung cancer                                        HCQ,\                                         Phase 2          Not provided                  Not yet recruiting        Mar 2016         Nov 2016
                                                                                        Gemcitabine,\                                                                                                                           
                                                                                        Carboplatin,\                                                                                                                           
                                                                                        Etoposide                                                                                                                               

  NCT00486603             Brain and central nervous system tumours                      HCQ,\                                         Phase 1 - 2      US                            Unknown                   June 2007        May 2012
                                                                                        Temozolomide,\                                                                                                                          
                                                                                        Radiation                                                                                                                               

  NCT00568880             Multiple myeloma and plasma cell neoplasms                    HCQ,\                                         Phase 3          US                            Unknown                   Dec 2007         July 2009
                                                                                        Bortezomib                                                                                                                              

  NCT00809237             Non-small cell lung cancer                                    HCQ,\                                         Phase 1 - 2      Singapore                     Unknown                   Dec 2008         Dec 2013
                                                                                        Gefitinib                                                                                                                               

  NCT01227135             Chronic myeloid leukaemia                                     HCQ,\                                         Phase 2          UK                            Unknown                   Oct 2010         Nov 2011
                                                                                        Imatinibmesylate                                                                                                                        

  NCT01292408             Breast cancer                                                 HCQ                                           Phase 2          The Netherlands               Unknown                   Dec 2010         Jan 2012
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: FOLFOX6 (folinic acid -- 5- fluorouracil -- oxaliplatin), XELOX (capecitabine -- oxaliplatin), IL-2 (interleukin-2), TACE (trans catheter arterial chemoembolisation), DCVAC (dendritic-cell based immunotherapy)

###### Publications reporting clinical trial results on CQ use in cancer.

  Article                              Tumour type                                Phase                                       Intervention                                    CQ dose         \# patients                Therapeutic response
  ------------------------------------ ------------------------------------------ ------------------------------------------- ----------------------------------------------- --------------- -------------------------- ----------------------
  Briceño *et al* \[[@ref38]\]         Glioblastoma multiforme                    Unknown                                     CQ + conventional cancer treatment              150 mg/day      18 (9 CQ + 9 control)      Positive
  Sotelo *et al* \[[@ref39]\]          Glioblastoma multiforme                    Phase 3                                     CQ + conventional cancer treatment              150 mg/day      30 (15 CQ + 15 control)    Partial
  Briceño *et al* \[[@ref41]\]         Glioblastoma multiforme                    Retrospective study based on patient data   CQ + conventional cancer treatment              150 mg/day      123 (41 CQ + 82 control)   Positive
  Rojas-Puentes *et al* \[[@ref43]\]   Brain metastases                           Phase 2                                     CQ + radiotherapy                               150 mg/day      73 (39 CQ + 34 control)    Partial
  Eldredge *et al* \[[@ref44]\]        Brain metastases                           Unknown                                     CQ + radiotherapy                               250 mg/day      20 (all CQ, no control)    Partial
  Montanari *et al* \[[@ref49]\]       Relapsed and refractory multiple myeloma   Phase 1 - 2                                 CQ + bortezomib + cyclophosphamide              500 mg/day      8 (all CQ, no control)     Partial
  Kyle *et al* \[[@ref50]\]            Multiple myeloma                           Unknown                                     CQ + prednisone + cyclophosphamide + caffeine   2x 250 mg/day   38 (18 CQ + 20 control)    Absent

###### Publications reporting clinical trial results on HCQ use in cancer.

  Article                           Tumour type                                Phase        Intervention                        HCQ dose             \# patients                Therapeutic response
  --------------------------------- ------------------------------------------ ------------ ----------------------------------- -------------------- -------------------------- --------------------------------------
  Rangwala *et al* \[[@ref51]\]     Advanced solid tumours and melanoma        Phase 1      HCQ + temsirolimus                  RD: 2x 600 mg/day    39 (all HCQ, no control)   Partial
  Rangwala *et al* \[[@ref52]\]     Advanced solid tumours and melanoma        Phase 1      HCQ + temozolomide                  RD: 2x 600 mg/day    40 (all HCQ, no control)   Partial
  Mahalingam *et al* \[[@ref53]\]   Advanced solid tumours                     Phase 1      HCQ + vorinostat                    MTD: 600 mg/day      27 (all HCQ, no control)   Partial
  Chi *et al* \[[@ref54]\]          Stage IV solid tumours                     Pilot        HCQ + sirolimus + chemotherapy      400 mg/day           25 (all HCQ, no control)   Partial
  Rosenfeld *et al* \[[@ref55]\]    GBM                                        Phase 1--2   HCQ + radiotherapy + temozolomide   MTD: 600 mg/day      92 (all HCQ, no control)   Absent
  Goldberg *et al* \[[@ref57]\]     Advanced NSCLC                             Phase 1      HCQ + erlotinib                     RD: 1000 mg/day      27 (all HCQ, no control)   Partial
  Vogl *et al* \[[@ref59]\]         Relapsed and refractory multiple myeloma   Phase 1      HCQ + bortezomib                    RD: 2x 600 mg/day    25 (all HCQ, no control)   Partial
  Boone *et al* \[[@ref60]\]        Pancreatic adenocarcinoma                  Phase 1--2   HCQ + gemcitabine                   RD: 1200 mg/day      35 (all HCQ, no control)   Partial
  Wolpin *et al* \[[@ref61]\]       Metastatic pancreatic adenocarcinoma       Phase 2      HCQ                                 400 and 600 mg/day   20 (all HCQ, no control)   Absent
  Chi *et al* \[[@ref62]\]          Sarcoma                                    Phase 2      HCQ + sirolimus                     2x 200 mg/day        10 (all HCQ, no control)   Absent, study was closed prematurely

Abbreviations: MTD (maximal tolerated dose), RD (recommended dose), NSCLC (non-small cell lung cancer)
